Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash Azitra, Inc. to Present at BIO Investment & Growth Summit Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates Azitra, Inc. Addresses False Report Regarding Sale of Securities